Current information from the U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (updated October 10, 2006) for treatment-naïve individuals is as follows:
Clinicians are recommended to construct a regimen by choosing one component from Column A plus one component from Column B |
| |
Column A |
Column B |
 |
|
|
| |
|
2-NRTI |
| Preferred (alphabetical order) |
| Efavirenz 1 |
Atazanavir + ritonavir
Fosamprenavir + ritonavir (twice daily)
Lopinavir/ritonavir (twice daily) |
|
Tenofovir/emtricitabine 3
Zidovudine/lamivudine |
| Alternative (alphabetical order) |
| Nevirapine 2 |
Atazanavir 4 (unboosted)
Fosamprenavir (unboosted)
Fosamprenavir + ritonavir once daily
Lopinavir/ritonavir once daily |
|
Abacavir/lamivudine 3
Didanosine + lamivudine 3 |
|
- Except during first trimester of pregnancy or in women with high pregnancy potential
- Nevirapine should not be initiated in women with CD4+ T-cell count greater than 250 cells/mm3 or in men with CD4+ T-cell count greater than 400 cells/mm3
- Emtricitabine and lamivudine are interchangeable
- Atazanavir must be boosted with ritonavir if used in combination with tenofovir.
|
Editor’s note: Above drug names are generic. Please refer to the Positively Aware January/February HIV Drug Guide table of contents or individual drug pages for brand names, or visit www.tpan.com.
For a full version of the DHHS guidelines, visit www.aidsinfo.nih.gov. |
